The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...

In short, fatty liver might seem harmless at first, but ignoring it can lead to life-threatening problems like cirrhosis, ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are several reasons for the name change.

Fatty liver disease is a common health issue. It is often linked to weight and lifestyle. Early detection is key to prevent ...

The global non-alcoholic steatohepatitis clinical trials market is on a significant upward trajectory, projected to grow from USD 2,964.4 million in 2025 to USD 5,806.8 million by 2035, according to ...